

## CONTENTS

### **Editorial**

- 1 **Elimination of leprosy as a public health problem.** S. K. NOORDEEN

### **Original Articles**

- 5 **Thalidomide's effectiveness in erythema nodosum leprosum is associated with a decrease in CD4+ cells in the peripheral blood.** E. J. SHANNON, MESTAWAT EJIGU, H. S. HAILE-MARIAM, TEBEBE YEMANE BERHAN and GENET TASESSE
- 12 **Prevalence of IgM antibodies to phenolic glycolipid I among household contacts and controls in Korea and the Philippines.** SANG-NAE CHO, SEONG HWA-KIM, R. V. CELLONA, GERTRUDE P. CHAN, T. T. FARJARDO, G. P. WALSH and JOO-DEUK KIM
- 21 **Follow-up of multibacillary leprosy patients using a phenolic glycolipid-I-based ELISA. Do increasing ELISA-values after discontinuation of treatment indicate relapse?** R. A. M. CHIN-A-LIEN, W. R. FABER, M. M. VAN RENS, D. L. LEIKER, B. NAAFS and P. R. KLATSER
- 28 **Detection of a *Mycobacterium leprae* cell wall antigen in the urine of untreated and treated patients.** V. K. SHARMA, S. KAUR, C. VAISHNAVI, N. AGNIHOTRI, I. KAUR and N. K. GANGULY
- 36 **Ambulatory treatment of multibacillary leprosy with a regimen of 8 months duration.** S. R. PATTYN, J. BOURLAND and KAZEZE
- 41 **Treatment of multibacillary leprosy with a regimen of 13 weeks duration.** S. R. PATTYN, G. GROENEN, L. JANSSENS, L. KUYKENS and L. B. MPUTU
- 47 **Red discoloration of the sputum by clofazimine simulating haemoptysis—a case report.** A. GIRDHAR, K. VENKATESAN, S. L. CHAUHAN, G. N. MALAVIYA and B. K. GIRDHAR
- 51 **Community-based rehabilitation: an evaluation study.** W. GERSHON and G. R. SRINIVASAN

### **Special Articles**

- 60 **Early detection of damage to nerves in leprosy.** D. D. PALANDE and R. E. M. BOWDEN
- 73 **Considerations in the integration of eye care into leprosy care services.** P. COURTRIGHT and SUSAN LEWALLEN

### **Obituary**

- 78 DAVID AKINWUNMI AKINTONDE

### **Letters to the Editor**

- 79 **An inexpensive slide marker made from a dental bur and plastic pen.** A. C. McDougall
- 80 **Eight years of follow-up of paucibacillary patients treated with short-course regimens.** S. R. PATTYN, G. GROENEN, J. BOURLAND, G. GRILLONE, L. KUYKENS and P. STES
- 82 **Agranulocytosis during multidrug therapy (MDT) of leprosy.** P. REEVE
- 83 **Comment: Recent advances in the antimicrobial chemotherapy of leprosy.** J. G. ALMEIDA
- 87 **Reply:** B. JI and J.-H. GROSSET
- 88 **Comment: Immunological upgrading with combined immunotherapy and chemotherapy in a lepromatous leprosy patient: a case report.** V. N. SEHGAL, S. N. BHATTACHARYA and S. JAIN
- 89 **Comment: Reversal reactions in leprosy and their management.** B. KULKARNI

91 **Teaching Materials and Services**

Centre for Social Science Research on Leprosy, India • School of Medical Education, NWS, Australia • A leprosy course in Maputo, Mozambique • Leprosy: basic information and management—now in Indonesian • *Essential Drugs Monitor*, WHO

94 **News and Notes**

New, improved 'genetic vaccines' for tropical diseases • ActionAid Disability News, India • Psoriatic lesions measure, Thames Laboratories, UK • International Leprosy Seminar, Turkey, September 1991 • Implementing multiple drug therapy for leprosy, OXFAM, UK